Celdara Medical, LLC announced today that it has received a $2.1M SBIR Phase II award from the National Institutes of Health’s National Heart, Lung, and Blood Institute (NHLBI). This award will support the preclinical development of Celdara Medical’s dendritic cell targeted therapy for myocardial infarction-induced ischemia-reperfusion injury.
“Myocardial infarction is one of the greatest health challenges of our generation,” said Jake Reder, Ph.D., cofounder and CEO of Celdara Medical. “The use of stents and thrombolytics has dramatically improved outcomes, but while the ischemic event must be resolved, it is actually the reperfusion itself which causes the majority of the damage to the myocardium. This results in unacceptable morbidity and mortality, and accounts for a significant portion of overall healthcare spending. According to our preclinical data, we appear to have a unique and highly efficacious strategy for mitigating reperfusion injury.”
By modulating the function of dendritic cells in a mouse model of myocardial infarction, Celdara Medical has been able to dramatically improve outcomes – both in terms of survival and cardiac function. This grant will allow Celdara Medical to complete preclinical studies and submit an investigational new drug (IND) application to the FDA.
Research reported in this press release was supported by the National Heart, Lung and Blood Institute of the National Institutes of Health under award number R44HL097464- 03. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
About Celdara Medical, LLC
Celdara Medical was founded by Drs. Jake Reder and Michael Fanger in 2008, and is headquartered at the Dartmouth Regional Technology Center (DRTC) in Lebanon, NH. Celdara Medical builds academic and early-stage innovations into high-potential medical companies, identifying discoveries of exceptional value at the earliest stages and moving them toward the market. Celdara Medical partners with inventors and their institutions, providing the developmental, financial, and business acumen required to bridge discovery and profitability. With robust funding options, a diverse and high impact Programmatic pipeline, and partnerships with world-class academic institutions and industry leaders, Celdara Medical navigates all aspects of a complex industry, accelerating science to improve human health.